Abstract:Acute myeloid leukemia (AML) is a devastating hematopoietic malignancy. The vast majority of AML patients are immediately refractory to induction therapy or subsequently relapses following transient complete remission, due to persistence of treatment-resistant leukemia stem cells (LSC). Thus, there is a clear need to identify new targets and develop novel and effective therapeutic approaches in this population. HDM2, an E3 ubiquitin-protein ligase, binds to p53 tumor suppressor in the cytoplasm, repressing p53 transcriptional activity and facilitating its proteasomal degradation. Overexpression of HDM2 plays a key role in tumorigenesis. Recently, it has been reported that HDM2 is not only localized to the cytoplasm but can also be found highly expressed on the plasma membrane of various cancer cells (i.e., colon, breast, pancreas) but not on normal counterparts (PNAS 2010 :107(5):1918-23). PNC-27(Oncolyze, Inc.), a 32-amino acid synthetic peptide with a penetratin domain and a HDM-2-binding domain of p53, can bind with cell membrane HDM2, causing membrane pore formation, thus inducing necrosis in solid tumor cells. However, the activity of PNC-27 in AML has not been established. Using flow cytometry analysis and confocal microscopy with anti-HDM2 antibody (Santa Cruz,N-20), we showed that HDM2 was expressed on the membrane of LSC-enriched CD34+CD38- primary blast populations procured from consecutive AML patients (n=6) at levels greater than those observed on normal CD34+CD38- cells [hematopoietic stem cells (HSC)] from healthy individuals (n=12) [median fluorescence intensity (MFI) (HDM-2/IgG control) 2.5±0.6 vs 1.1±0.1; p<0.01)]. Similar results were also observed in AML cell lines (i.e., THP-1, MV4-11,MOLM-13, NOMO1).Further, we showed that exposure to PNC-27 (50-200ug/ml) for 72 hours resulted in significantly reduced viability and colony formation activity (P<0.001) in both AML cell lines and human AML CD34+ cells compared with normal CD34+ cells, in a dose- and time-dependent manner. PNC-27 antileukemia activity was significantly and directly correlated with cell membrane HDM2 expression levels (p<0.05), more HDM2 expression, higher PNC-27 efficacy. Confocal microscopy using fluorescent anti-HDM2 and anti-PNC-27 antibodies showed that PNC-27 and HDM-2 co-localized to the membrane of primary AML CD34+ blasts. Consistent with the previous studies, we also observed membrane pore formation by electron microscopy and cell necrosis by increased LDH levels rather than apoptosis(no change in Annexin V+ cell percentage and pro-apoptosis protein levels) in PNC-27 treated cells.

PFR peptide, one of the antimicrobial peptides identified from the derivatives of lactoferrin, induces necrosis in leukemia cells

Proteinase-Activated Receptor 1 Expression in Human Leukemia Hl-60 Cells and Its Significance.

PNC¯27 Targeting Plasma Membrane HDM2: A Potentially Novel Therapeutic Approach for Acute Myeloid Leukemia (AML)

Recombinant human lactoferrin carrying humanized glycosylation exhibits antileukemia selective cytotoxicity, microfilament disruption, cell cycle arrest, and apoptosis activities

Antitumor Effects with Apoptotic Death in Human Promyelocytic Leukemia Hl-60 Cells and Suppression of Leukemia Xenograft Tumor Growth by Irinotecan Hcl

P7 Peptides Suppress the Proliferation of K562 Cells Induced by Basic Fibroblast Growth Factor

Lactoferricin B Combined with Antibiotics Exhibits Leukemic Selectivity and Antimicrobial Activity

Antimicrobial Peptide Brevinin-1RL1 from Frog Skin Secretion Induces Apoptosis and Necrosis of Tumor Cells

Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy

Discovery of novel selective phosphodiesterase‐1 inhibitors for the treatment of acute myelogenous leukemia

Lysosomal Membrane‐Biomimetic Metal‐Organic Framework Potentiates Autophagy/Epigenetic‐Mediated Anti‐Tumor Immunity

Generation and Preclinical Characterization of an Nkp80-Fc Fusion Protein for Redirected Cytolysis of Natural Killer (nk) Cells Against Leukemia

Proteasome inhibitors FHND6091 enhance the ability of NK cells to kill tumor cells through multiple mechanisms

Suppression of Tumor Growth and Metastasis by a VEGFR-1 Antagonizing Peptide Identified from a Phage Display Library.

PLGA-PLL-PEG-Tf-based Targeted Nanoparticles Drug Delivery System Enhance Antitumor Efficacy Via Intrinsic Apoptosis Pathway

The Imidazacridine Derivative LPSF/AC-05 Induces Apoptosis, Cell Cycle Arrest, and Topoisomerase II Inhibition in Breast Cancer, Leukemia, and Lymphoma

Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells

A Pyridinesulfonamide Derivative FD268 Suppresses Cell Proliferation and Induces Apoptosis Via Inhibiting PI3K Pathway in Acute Myeloid Leukemia

A Novel Fgfr1-Binding Peptide Exhibits Anti-Tumor Effect On Lung Cancer By Inhibiting Proliferation And Angiogenesis

Strategy to Enhance Anticancer Activity and Induced Immunogenic Cell Death of Antimicrobial Peptides by Using Non-Nature Amino Acid Substitutions

Lactoferrin-Derived Peptide Chimera Induces Caspase-independent Cell Death in Multiple Myeloma